Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05338801 · ClinicalTrials.gov registry record · NA

Effect of Menthol on ENDS Users' Addiction and Exposure

A NA study of Electronic Cigarette Use, sponsored by Florida International University.

Recruiting
Registry status
NA
Development phase
250
Enrollment target
1
Study location

NCT05338801 is a NA study of Electronic Cigarette Use that is actively recruiting participants, run by Florida International University. The registered enrollment target is 250 participants, above the 196-participant average among 15 other Electronic Cigarette Use trials with a reported enrollment target (28% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05338801, a NA study of Electronic Cigarette Use, is actively recruiting participants, sponsored by Florida International University.

RECRUITING
Registry status
NA
Development phase
250 participants
Enrollment target
1
Study location

Study Summary

The use of electronic nicotine delivery systems (ENDS; e-cigarettes) has reached epidemic levels among young people in the United States (US). ENDS heat and vaporize a nicotine-containing liquid to produce an inhalable aerosol mist. While generally considered less harmful than combustible cigarettes, ENDS use exposes users to dependence-producing nicotine and respiratory and cardiovascular toxicants such as aldehydes. Flavor is a major factor in getting young people to use ENDS, thus limiting flavors to menthol and tobacco for prefilled cartridge ENDS "pod mods" was the first major action taken by the FDA to reduce the spread of ENDS among young people. Menthol flavor, however, can present a potential risk given its increasing popularity among young people in the US, and its puffing and nicotine-enhancing properties. Yet, the extent of menthol's ability to affect users' experience and puffing patterns, and how these affect dependence, exposure to toxicants, and clinical outcomes continue to be understudied. Such evidence will be critical to the FDA's ability to set further regulatory standards to reduce ENDS potential harm. The investigators will conduct a 2x2 (pre-post x menthol vs. tobacco flavor) crossover clinical lab study. The investigator will recruit current/past month ENDS users (n=250, 21-35 yrs), who will attend two sessions and use their ENDS once with menthol and once with tobacco flavors. The proposed studies will answer two key regulatory questions consistent with FDA's focus on the role of flavor in tobacco products' addiction and toxicity; 1) compared to tobacco flavor, does menthol carry additional risk by enhancing puffing, abuse liability, and toxicant exposure in ENDS users, and; 2) is this effect more pronounced among high dependence compared to other users. Other outcomes such as harm perception, satisfaction, clinical responses, intention to use or quit, and group comparisons such as according to race, and sex will allow the FDA a comprehensi

Conditions Studied

Interventions

  • OTHER Menthol-flavored e-cigarette
  • OTHER Tobacco-flavored e-cigarette

Study Locations (1)

Florida

  • Florida International University - Miami

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2022-06-22
Est. Completion 2027-03-31
Phase NA

Sponsor

Florida International University

89 total trials

What the Registry Record Tells You About NCT05338801

The ClinicalTrials.gov registry entry for NCT05338801 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 15 other Electronic Cigarette Use trials with a reported enrollment target (28% higher). The listed sponsor is Florida International University, which has 89 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Electronic Cigarette Use appearing as the primary indexed condition, and to 2 interventions - of which Menthol-flavored e-cigarette is the first listed.

NCT05338801 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05338801 about?

NCT05338801 is a clinical study titled "Effect of Menthol on ENDS Users' Addiction and Exposure". The use of electronic nicotine delivery systems (ENDS; e-cigarettes) has reached epidemic levels among young people in the United States (US). ENDS heat and vaporize a nicotine-containing liquid to produce an inhalable aerosol mist. While generally considered less harmful than combustible cigarettes...

What is the current status of trial NCT05338801?

This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2022-06-22. Estimated completion is 2027-03-31.

What conditions does trial NCT05338801 study?

This clinical trial studies the following conditions: Electronic Cigarette Use.

What interventions are being tested in trial NCT05338801?

The interventions under investigation include: Menthol-flavored e-cigarette (OTHER), Tobacco-flavored e-cigarette (OTHER).

Who is sponsoring clinical trial NCT05338801?

This trial is sponsored by Florida International University, which has 89 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05338801 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Electronic Cigarette Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.